Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Measurements of Breast Tissue Optical Properties

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by University of California, Irvine
Sponsor:
Collaborators:
International Medical Center of Japan
University of California, San Diego
Information provided by (Responsible Party):
Montana Compton, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT00540540
First received: October 4, 2007
Last updated: November 6, 2014
Last verified: November 2014
  Purpose

Currently, breast cancer will kill over 40,000 women in the United States this year. 2.5 million women alive today have been diagnosed with breast cancer at some time in their lifetimes. Despite an increasing incidence, the age-adjusted death rate from carcinoma has remained relatively stable. Effective screening and treatment are both necessary to reduce mortality. Screening mammography as an early detection technique has been estimated to reduce mortality by as much as 23% but is limited in its ability to detect lesions in high density breast tissue common in younger women.


Condition Intervention
Accessory; Breast Tissue
Device: Diffuse Optical Spectroscopy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurements of Breast Tissue Optical Properties

Further study details as provided by University of California, Irvine:

Primary Outcome Measures:
  • Healthy Breast [ Time Frame: up to 4 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 600
Study Start Date: December 1995
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Diffuse Optical Spectroscopy
    Breast properties scanning
Detailed Description:

The Diffuse Optical Spectroscopic Imaging can monitor the change in breast tissues. Researcher can use Diffuse Optical Spectroscopic Imaging to monitoring early response to some therapies and can determine malignant, benign, and healthy breast tissue.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Study population will be selected from University of California Irvine Medical Clinic and Cancer Center.

Criteria

Inclusion Criteria:

  • Non-pregnant woman age 18 yrs and older.

Exclusion Criteria:

  • pregnant woman and younger than 18 yrs of age.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00540540

Contacts
Contact: Montana Compton, RN 949-825-9265 ext 9265 mocomton@uci.edu

Locations
United States, California
Pacific Breast Care Medical Clinic Recruiting
Costa Mesa, California, United States, 92627
Contact: Montana Compton, RN    949-824-9265    mocomton@uci.edu   
Sub-Investigator: Alice Police, MD         
Sub-Investigator: Thomas O'Sullivan, PhD         
Sub-Investigator: Montana Compton, RN         
Sub-Investigator: Anais Leproux, PhD         
Beckman Laser Institute University of California Irvine Recruiting
Irvine, California, United States, 92612
Contact: Montana Compton, RN    949-824-9265 ext 9265    mocomton@uci.edu   
Principal Investigator: Bruce J Tromberg, Ph.D.         
Sub-Investigator: Albert Cerussi, Ph.D         
Sub-Investigator: Montana Compton, RN         
Sub-Investigator: Amanda Durkin, BS         
Sub-Investigator: Anais Leproux, PhD         
Sub-Investigator: Thomas O'Sullivan, Ph.D.         
Chao Family Comprehensive Cancer Center, UCIMC Recruiting
Orange, California, United States, 92868
Contact: Montana Compton, RN    949-824-9265    mocomton@uci.edu   
Sub-Investigator: David Hsiang, MD         
Sub-Investigator: John Butler, MD         
Sub-Investigator: Karen Lane, RN         
Sub-Investigator: Rita Mehta, MD         
Sub-Investigator: Montana Compton, RN         
Sub-Investigator: Anais Leproux, PhD         
Sub-Investigator: Thomas O'Sullivan, PhD         
Sub-Investigator: Amanda Durkin, BS         
Sponsors and Collaborators
Montana Compton
International Medical Center of Japan
University of California, San Diego
Investigators
Principal Investigator: Bruce J Tromberg, Ph.D Beckman Laser Institute
  More Information

No publications provided

Responsible Party: Montana Compton, Administrative Nurse Research Coordinator Beckman Laser Institute, University of California, Irvine
ClinicalTrials.gov Identifier: NCT00540540     History of Changes
Other Study ID Numbers: NIH/LAMMP-1995-563
Study First Received: October 4, 2007
Last Updated: November 6, 2014
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on November 25, 2014